Molecular Cancer Therapeutics

Table of Contents

AACR American Association for Cancer Research

August 2016 • Volume 15 • Number 8

Highlights of This Issue 1779

REVIEWS

1781 **ATM Mutations in Cancer: Therapeutic Implications**
Michael Choi, Thomas Kipps, and Razelle Kurzrock

1792 **Concepts to Target MYC in Pancreatic Cancer**
Matthias Wirth, Siavosh Mahboobi, Oliver H. Krämer, and Günter Schneider

SMALL MOLECULE THERAPEUTICS

1799 **Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma**
Daniel Markowitz, Caitlin Powell, Nhan L. Tran, Michael E. Berens, Timothy C. Ryken, Magimairajan Vanan, Lisa Rosen, Mingzhu He, Shan Sun, Marc Symons, Yousef Al-Abed, and Rosamaria Ruggieri

1809 **Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer**
Varvara K. Kozyreva, Anna A. Kiseleva, Ryan J. Ice, Brandon C. Jones, Yuriy V. Loskutov, Fatimah Matalkah, Matthew B. Smolkin, Kristina Marinak, Ryan H. Livengood, Mohamad A. Salkeni, Sijin Wen, Hannah W. Hazard, Ginger P. Layne, Callee M. Walsh, Pamela S. Cantrell, Greg W. Kilby, Sricharan Mahavadi, Neal Shah, and Elena N. Pugacheva

1823 ***In Silico* Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment**
Javier Pérez-Peña, Gemma Serrano-Heras, Juan Carlos Montero, Verónica Corrales-Sánchez, Atanasio Pandiella, and Alberto Ocaña

1834 **Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen**
Xinning Wang, Brian Tsui, Gopolakrishnan Ramamurthy, Ping Zhang, Joseph Meyers, Malcolm E. Kenney, Jonathan Kiechle, Lee Ponsky, and James P. Basilion

1845 **Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells *In Vitro*, *In Vivo*, and *Ex Vivo***
Zhen Chen, Yifan Chen, Meng Xu, Likun Chen, Xu Zhang, Kenneth Kin Wah To, Hongyun Zhao, Fang Wang, Zhongjun Xia, Xiaoqin Chen, and Liwu Fu

1859 **The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas**
Jessie Peh, Timothy M. Fan, Kathryn L. Wycislo, Howard S. Roth, and Paul J. Hergenrother

LARGE MOLECULE THERAPEUTICS

1870 **A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity**
Michael L. Miller, Nathan E. Fishkin, Wei Li, Kathleen R. Whiteman, Yelena Kovtun, Emily E. Reid, Katie E. Archer, Erin K. Maloney, Charlene A. Audette, Michele F. Mayo, Alan Wilhelm, Holly A. Modafferi, Rajeeva Singh, Jan Pinkas, Victor Goldmacher, John M. Lambert, and Ravi V.J. Chari

1879 **Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells**
Ramraj Velmurugan, Dilip K. Challa, Sripad Ram, Raimund J. Ober, and E. Sally Ward

1890 **A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells**
Matthieu Broussas, Nicolas Boute, Barbara Akla, Sven Berger, Charlotte Beau-Larvor, Thierry Champion, Alain Robert, Alain Beck, Jean-François Haeuw, Liliane Goetsch, Christian Bailly, Charles Dumontet, Thomas Matthes, Nathalie Corvaia, and Christine Klinguer-Hamour

1900 **SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression**
Jonathan Black, Gulden Menderes, Stefania Bellone, Carlton L. Schwab, Elena Bonazzoli, Francesca Ferrari, Federica Predolini, Christopher De Haydu, Emiliano Cocco, Natalia Buza, Pei Hui, Serena Wong, Salvatore Lopez, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Babak Litkouhi, Peter E. Schwartz, Peter Goedings, Patrick H. Beusker, Miranda M.C. van der Lee, C. Marco Timmers, Wim H.A. Dokter, and Alessandro D. Santin

1910 **Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers**
Chien-Hsing Chang, Yang Wang, Maria Zalath, Donglin Liu, Thomas M. Cardillo, and David M. Goldenberg

Table of Contents

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

1920 **Protection against HPV-16–Associated Tumors Requires the Activation of CD8$^+$ Effector Memory T Cells and the Control of Myeloid-Derived Suppressor Cells**
Mariana O. Diniz, Natiely S. Sales, Jamile R. Silva, and Luís Carlos S. Ferreira

1931 **Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages**
Stephen Iwanowycz, Junfeng Wang, Johnie Hodge, Yuzhen Wang, Fang Yu, and Daping Fan

1943 **Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals**
Le Tao, Jianxin Qiu, Ming Jiang, Wenbin Song, Shuyuan Yeh, Hong Yu, Lijuan Zang, Shujie Xia, and Chawnshang Chang

1952 **The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer**
Thomas C. Beadnell, Katie M. Mishall, Qiong Zhou, Stephen M. Riffert, Kelsey E. Wuensch, Brittelle E. Kessler, Maia L. Corpuz, Xia Jing, Jihye Kim, Guoliang Wang, Aik Choon Tan, and Rebecca E. Schweppe

1964 **Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer**
Casey Stottrup, Tiffany Tsang, and Y. Rebecca Chin

1975 **ERK1 as a Therapeutic Target for Dendritic Cell Vaccination against High-Grade Gliomas**
Min-Chi Ku, Inan Edes, Ivo Bendix, Andreas Pohlmann, Helmar Waiczies, Tim Prozorovski, Martin Günther, Conrad Martin, Gilles Pagès, Susanne A. Wolf, Helmut Kettenmann, Wolfgang Uckert, Thoralf Niendorf, and Sonia Waiczies

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

1988 **Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic *HER4* Mutations in HNSCC**
Yu Nakamura, Yosuke Togashi, Hirokazu Nakahara, Shuta Tomida, Eri Banno, Masato Terashima, Hidetoshi Hayashi, Marco A. de Velasco, Kazuko Sakai, Yoshihiko Fujita, Takatsugu Okegawa, Kikuo Nutahara, Suguru Hamada, and Kazuto Nishio

1998 **High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide**
Amy D. Guertin, Jennifer O'Neil, Alexander Stoeck, Joseph A. Reddy, Razvan Cristescu, Brian B. Haines, Marlene C. Hinton, Ryan Dorton, Alicia Bloomfield, Melissa Nelson, Marilynn Vetzel, Serguei Lejnine, Michael Nebozhyn, Theresa Zhang, Andrey Loboda, Kristen L. Picard, Emmett V. Schmidt, Isabelle Dussault, and Christopher P. Leamon

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The cover shows a schematic of the mechanism of action of an antibody–drug conjugate (ADC) utilizing a new class of DNA alkylating agent as the cytotoxic payload (shown as a red circle). Its antibody component enables the ADC to bind specifically to cancer cells expressing its antigen target. Once bound, the conjugate is internalized and the cytotoxic payload is released. For ADCs with a cleavable linker, this release can be through linker cleavage, as shown, as well as through lysosomal degradation of the antibody component. The released DNA alkylating agent can disrupt the DNA in its cell of release, causing cell death. With a cleavable linker, it can also enter an adjacent cancer cell and kill it. For details, see the article by Miller and colleagues beginning on page 1870.

Molecular Cancer Therapeutics

15 (8)

Mol Cancer Ther 2016;15:1779-2008.